Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
about
Structural and functional properties of platelet-derived growth factor and stem cell factor receptorsFunctional deregulation of KIT: link to mast cell proliferative diseases and other neoplasmsMast cell modulation of the vascular and lymphatic endotheliumTarget interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growthNovel targeted therapies for eosinophil-associated diseases and allergyAdvances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.Diagnosis and treatment of mast cell disorders: practical recommendations.Screening of candidate G-quadruplex ligands for the human c-KIT promotorial region and their effects in multiple in-vitro models.Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor β chain and KIT V654A.Mastocytosis: a mutated KIT receptor induced myeloproliferative disorderSignal transduction and chemotaxis in mast cellsIdentification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation.Symptomatic response to imatinib mesylate in cutaneous mastocytosis associated with chronic myelomonocytic leukemia.Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progressionSynergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816VPak and Rac GTPases promote oncogenic KIT-induced neoplasms.Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: a case review.Mastocytosis: update on pharmacotherapy and future directions.Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disordersMastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.C-kit mutations determine dasatinib mechanism of action in HMC-1 neoplastic mast cells: dasatinib differently regulates PKCδ translocation in HMC-1(560) and HMC-1(560,816) cell lines.Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.Different role of cAMP pathway on the human mast cells HMC-1(560) and HMC-1(560,816) activation.Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Identification of Biological and Pharmaceutical Mast Cell- and Basophil-Related Targets.How we diagnose and treat systemic mastocytosis in adults.Midostaurin: a magic bullet that blocks mast cell expansion and activation.A transgenic zebrafish model expressing KIT-D816V recapitulates features of aggressive systemic mastocytosis.Bosutinib, a Lyn/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis.Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia.BLU-285-the breakthrough in treatment of patients with aggressive systemic mastocytosis and gastrointestinal stromal tumor.Aggressive systemic mastocytosis of the liver with cholangitis
P2860
Q26829546-CB5E9168-15E7-43B7-A03C-797735D83093Q26995624-B5AF332F-D252-4E63-98A3-FED96446322DQ27687421-6AA1B851-BECC-4D4A-AC11-8D8DEF6BD28AQ28828739-11F7C43E-2F67-4F17-913A-10503A4DD89FQ34444620-22E6D011-2AE5-4BE3-91B5-DF342BD362A0Q34552564-8D65CA81-4C6D-4393-BBB0-1F71A4FE005CQ34663691-0427AE21-72C9-474A-80A0-F8FC63EA75C1Q34664111-80850FFF-5A4C-423F-80AF-1B205DEA993EQ35021196-2D75FF08-7B62-46E4-A8A9-433EAD2D3789Q35945953-73236019-DB43-4589-BCBB-71CD86145DFEQ36012962-96EA6DF9-ED4D-4AE0-AD8C-FEE5269EFFE8Q36210845-4EECA43C-5DCE-4EB3-BB57-CC6BC1E258CAQ36240848-02871F1B-43E4-48C5-8365-5D221D714A84Q36406996-5DED23F1-57D6-4002-895E-780AC39F1E53Q36487624-F192848B-A2CC-4B97-8DF4-B6C3E648A2E3Q37056908-53C1D299-AEC7-478B-9355-646134DD0D69Q37142455-F797F62E-6C36-42CE-8FCC-57A6717633BEQ37144902-51176192-D4D7-43AA-A066-507B885721D3Q37200848-EA1DB80B-5172-4B89-98D0-0676D03D7673Q37955869-BAA2BDAD-257D-42A4-8209-AC10AC05D8C6Q38138597-84C9FBFC-8E5C-493E-AB60-5F70D32A6F31Q38202204-A8425C1C-4EB9-47AD-B12D-0E39DDB5F521Q38777126-A8F57792-3A51-4670-80A9-CB5D8852CB17Q38852257-1F8BF694-EEA6-4138-A3F5-E05177B909B9Q38866094-562D7878-20EF-46C6-AD35-5EACB2E07E8BQ39048486-098EC3A1-0BC3-4461-9043-2A3C645A9E2CQ40347748-622E1C43-977D-4FC4-B485-F9F8B818491EQ42376734-BF632571-2B11-4CA5-B2B4-E2EBFEF4A6EAQ47322561-A2AD9492-0B1A-409D-B2C0-2379E529F783Q47763014-5C461558-AF5B-4A7D-A2DC-8491AAB1095FQ47930594-A9B2C5A6-590A-491A-BEB4-2097F999EA42Q50651368-7088B240-7B34-46AF-A17B-14A689AC83AEQ52970799-A143B1E4-282E-43F1-BD5E-57C460C47CFEQ54546815-1C5BC021-2E66-4FB9-A62D-032D7111FDA9Q55286285-7A533146-C4EE-4943-AFFC-F12769BAF154Q55715469-FC4F1B9D-5F69-43FC-BC10-4DBAA2EAAEF2Q57142207-54D3311C-A037-4F44-ABB0-6E0F916BA1D3
P2860
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
@en
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
@nl
type
label
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
@en
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
@nl
prefLabel
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
@en
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
@nl
P1433
P1476
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis
@en
P2093
Celalettin Ustun
David L DeRemer
P304
P356
10.1016/J.LEUKRES.2011.05.006
P50
P577
2011-06-08T00:00:00Z